PMID- 37477769
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230901
IS  - 2193-8210 (Print)
IS  - 2190-9172 (Electronic)
VI  - 13
IP  - 9
DP  - 2023 Sep
TI  - The Efficacy of Sonidegib in Treating Locally Advanced Basal Cell Carcinoma 
      Involving the Periocular Area.
PG  - 2121-2126
LID - 10.1007/s13555-023-00985-1 [doi]
AB  - INTRODUCTION: Basal cell carcinoma (BCC) is the most common skin malignancy in 
      Caucasians. Globally, about 20% of BCCs involve the periocular region. The 
      treatment of periocular BCC may be very challenging because of its proximity to 
      the intracranial structures. Thus, early diagnosis and early treatment is 
      mandatory. Recently, the introduction of Hedgehog pathway inhibitor therapy 
      revolutionized the management of unresectable BCCs. The aim of our study was to 
      evaluate the outcome of sonidegib treatment in patients affected by periocular 
      locally advanced (la) BCC at our skin cancer center. METHODS: A 3-year 
      retrospective study was carried out enrolling patients with periocular laBCC 
      treated with sonidegib. Therapeutic response was defined as complete remission 
      (CR) in case of complete regression of the tumor, partial remission (PR) in case 
      of tumor regression not achieving complete remission, and stable disease (SD). 
      RESULTS: A total 16 patients (11 men and 5 women; medium age 71.6 +/- 11.5 years) 
      with periocular laBCCs undergoing treatment with 200 mg/day of sonidegib were 
      included in our study. Patients included in the study were treated for at least 
      6 months for a median duration of 9 months. Overall, CR was reported in 9/16 
      (56.2%) patients, PR was reported in 4/16 patients (25%), and tumor remained 
      stable in 3 patients (18.8%). No cases of disease progression were collected. 
      Fourteen out of 16 patients experienced multiple adverse events (AEs): dysgeusia 
      was reported in 12 (75%) patients, muscle spasms in 13 (81%) patients, and 7 
      (43.7%) patients presented with alopecia. However, all of the AEs were mild and 
      none required treatment discontinuation. CONCLUSION: To the best of our 
      knowledge, this is the first study investigating the effectiveness and safety of 
      sonidegib in the management of BCC localized at the periocular region. Even if 
      limited, our study suggests this drug as a valuable and safe option in periocular 
      BCC management.
CI  - (c) 2023. The Author(s).
FAU - Villani, Alessia
AU  - Villani A
AUID- ORCID: 0000-0001-6430-268X
AD  - Dermatology Unit, Department of Clinical Medicine and Surgery, University of 
      Naples Federico II, Via Pansini, 5, 80131, Naples, Italy. ali.vil@hotmail.it.
FAU - Fabbrocini, Gabriella
AU  - Fabbrocini G
AD  - Dermatology Unit, Department of Clinical Medicine and Surgery, University of 
      Naples Federico II, Via Pansini, 5, 80131, Naples, Italy.
FAU - Micali, Giuseppe
AU  - Micali G
AD  - Dermatology Clinic, University of Catania, Catania, Italy.
FAU - Fornaro, Luigi
AU  - Fornaro L
AD  - Dermatology Unit, Department of Clinical Medicine and Surgery, University of 
      Naples Federico II, Via Pansini, 5, 80131, Naples, Italy.
FAU - Potestio, Luca
AU  - Potestio L
AD  - Dermatology Unit, Department of Clinical Medicine and Surgery, University of 
      Naples Federico II, Via Pansini, 5, 80131, Naples, Italy.
FAU - Scalvenzi, Massimiliano
AU  - Scalvenzi M
AD  - Dermatology Unit, Department of Clinical Medicine and Surgery, University of 
      Naples Federico II, Via Pansini, 5, 80131, Naples, Italy.
LA  - eng
PT  - Journal Article
DEP - 20230721
PL  - Switzerland
TA  - Dermatol Ther (Heidelb)
JT  - Dermatology and therapy
JID - 101590450
PMC - PMC10442300
OTO - NOTNLM
OT  - Basal cell carcinoma
OT  - Hedgehog inhibitor
OT  - Skin cancer
OT  - Sonidegib
OT  - Vismodegib
EDAT- 2023/07/21 13:14
MHDA- 2023/07/21 13:15
PMCR- 2023/07/21
CRDT- 2023/07/21 11:09
PHST- 2023/05/09 00:00 [received]
PHST- 2023/07/13 00:00 [accepted]
PHST- 2023/07/21 13:15 [medline]
PHST- 2023/07/21 13:14 [pubmed]
PHST- 2023/07/21 11:09 [entrez]
PHST- 2023/07/21 00:00 [pmc-release]
AID - 10.1007/s13555-023-00985-1 [pii]
AID - 985 [pii]
AID - 10.1007/s13555-023-00985-1 [doi]
PST - ppublish
SO  - Dermatol Ther (Heidelb). 2023 Sep;13(9):2121-2126. doi: 
      10.1007/s13555-023-00985-1. Epub 2023 Jul 21.